Nomegestrol Stragen (Nomegestrol Acetate)

Nomegestrol acetate, the active ingredient in Nomegestrol Stragen, is a synthetic progestogen presented as an oral tablet for oral use. It is employed in hormonal contraception, the management of menstrual disorders, and hormone replacement therapy for women of reproductive age.

GNH USA supplies Nomegestrol Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers, including regulatory documentation and pharmacovigilance support throughout.

Nomegestrol Stragen, a synthetic progestogen, is used in hormonal pathways related to contraception and estrogen deficiency. - Contraception: Provides effective oral hormonal birth control by suppressing ovulation and inducing endometrial changes. - Menstrual disorder management: Alleviates irregular bleeding and dysmenorrhea by stabilizing the endometrial lining. - Hormone replacement therapy: Replaces deficient progesterone in post‑menopausal women to maintain hormonal balance.

Nomegestrol Stragen may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild stomach upset. - Headache: transient cranial pain. - Breast tenderness: mild discomfort. - Vaginal spotting: light bleeding between periods.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: elevated enzymes or jaundice.

When prescribing Nomegestrol Stragen, clinicians should consider several precautionary measures to ensure safe use. - Assess thrombotic risk: evaluate history of clotting disorders before initiating therapy. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Screen for hormone‑sensitive cancers: avoid use in patients with active breast or endometrial cancer. - Counsel on smoking: advise cessation, especially in women over 35, due to increased cardiovascular risk. - Review concomitant medications: consider potential interactions that may affect efficacy or safety. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Nomegestrol acetate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: such as rifampicin or phenytoin, which may reduce plasma levels. - Anticoagulants: increased risk of thrombosis when combined with estrogen‑containing products.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors: like ketoconazole, may raise drug concentrations. - Antiepileptic drugs: may affect hormonal balance. - Herbal supplements: St. John’s wort may decrease efficacy.